- Home
- CE vs TFX Comparison
CE vs TFX Comparison
Compare CE & TFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CE
- TFX
- Stock Information
- Founded
- CE 1918
- TFX 1943
- Country
- CE United States
- TFX United States
- Employees
- CE N/A
- TFX N/A
- Industry
- CE Major Chemicals
- TFX Medical/Dental Instruments
- Sector
- CE Industrials
- TFX Health Care
- Exchange
- CE Nasdaq
- TFX Nasdaq
- Market Cap
- CE 8.3B
- TFX 8.3B
- IPO Year
- CE 2005
- TFX N/A
- Fundamental
- Price
- CE $72.63
- TFX $181.27
- Analyst Decision
- CE Hold
- TFX Buy
- Analyst Count
- CE 16
- TFX 7
- Target Price
- CE $102.80
- TFX $252.50
- AVG Volume (30 Days)
- CE 2.2M
- TFX 476.9K
- Earning Date
- CE 02-18-2025
- TFX 02-20-2025
- Dividend Yield
- CE 3.86%
- TFX 0.75%
- EPS Growth
- CE N/A
- TFX N/A
- EPS
- CE 9.95
- TFX 5.03
- Revenue
- CE $10,479,000,000.00
- TFX $3,025,824,000.00
- Revenue This Year
- CE N/A
- TFX $4.52
- Revenue Next Year
- CE $1.07
- TFX $4.79
- P/E Ratio
- CE $7.29
- TFX $36.10
- Revenue Growth
- CE N/A
- TFX 2.27
- 52 Week Low
- CE $64.05
- TFX $171.69
- 52 Week High
- CE $172.16
- TFX $256.85
- Technical
- Relative Strength Index (RSI)
- CE 55.94
- TFX 49.27
- Support Level
- CE $70.21
- TFX $175.44
- Resistance Level
- CE $72.23
- TFX $185.35
- Average True Range (ATR)
- CE 1.96
- TFX 4.25
- MACD
- CE 1.39
- TFX 1.10
- Stochastic Oscillator
- CE 98.39
- TFX 67.80
About CE Celanese Corporation
Celanese is one of the world's largest producers of acetic acid and its downstream derivative chemicals, which are used in various end markets, including coatings and adhesives. The company is also one of the largest producers of specialty polymers, which are used in the automotive, electronics, medical, building, and consumer end markets. The company also makes cellulose derivatives used in cigarette filters.
About TFX Teleflex Incorporated
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2023 sales), interventional (17%), anesthesia (13%), surgical (14%), interventional urology (11%), original-equipment manufacturing (11%), and other (10%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.